A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients.
Human herpesvirus 6 (HHV-6) infection is potentially life-threatening to immunosuppressed patients. There is a lack of information regarding the risk and the clinical manifestations of primary HHV-6 infection in solid-organ transplant recipients. We prospectively evaluated patients undergoing solid organ transplantation with negative immunoglobulin (Ig) G antibodies against HHV-6 by means of HHV-6 quantitative polymerase chain reaction. Among 193 recipients, seven were HHV-6 seronegative (prevalence 3.6%). We detected a positive HHV-6 viral load in only one patient, and four patients seroconverted after one year posttransplantation. The patient with a positive HHV-6 viral load developed cholestatic hepatitis without fever and did not experience severe end-organ disease. In conclusion, our findings show a low incidence of symptomatic primary HHV-6 infection among seronegative solid-organ transplant recipients.
Cervera
Carlos
C
Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.
Marcos
María Angeles
MA
Linares
Laura
L
Roig
Eulalia
E
Benito
Natividad
N
Pumarola
Tomás
T
Moreno
Asunción
A
D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000009:adverse effects; D015654:Herpesvirus 6, Human / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation; D016035:Pancreas Transplantation / Q000009:adverse effects; D011183:Postoperative Complications / Q000821:virology*; D019349:Roseolovirus Infections / Q000453:epidemiology*; D013030:Spain; D013997:Time Factors
D007166:Immunosuppressive Agents